A Phase 1 interventional study of TGR-1202 + brentuximab vedotin in Hodgkin's Lymphoma, sponsored by TG Therapeutics, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-02.
Sponsored by TG Therapeutics, Inc. · Phase 1, Interventional, and Treatment
The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in combination with brentuximab vedotin in patients with hodgkin's lymphoma.
5,578 studies on the registry are indexed under Lymphoma; 825 are open to participants now.
This study's enrollment of 16 is below the median of 40 across 4,508 interventional studies indexed under Lymphoma.
Browse Lymphoma studies →TG Therapeutics, Inc. is the lead sponsor of 40 studies on the registry; 9 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
TGR-1202 oral daily dose in combination with a fixed IV infusion of brentuximab vedotin
Drug: TGR-1202 + brentuximab vedotin
TGR-1202 an oral daily dose with an IV infusion of brentuximab vedotin
Also known as: brentuximab vedotin: Adcetris
Maximum Tolerated Dose acceptable for participants
To determine the incidence of adverse events, any potential abnormal laboratory results and any dose-limiting toxicities
Time frame: 21 days (1 cycle of therapy)
Overall Response Rate
To assess the overall response rate (ORR) of TGR-1202 in combination with brentuximab vedotin in patients with Hodgkin's lymphoma
Time frame: Up to 1 year
Duration of Response
To evaluate the duration of response of TGR-1202 in combination with brentuximab vedotin
Time frame: Up to 1 year
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
TG Therapeutics, Inc.